Travere Therapeutics licensed global rights to civorebrutinib, a covalent reversible BTK inhibitor, in a deal valued at up to $1.14 billion. The transaction brings additional rare kidney disease focus, with Travere paying $112.5 million upfront to Everest Medicines and contingent milestones extending across as many as five indications, supported by proof-of-concept clinical evidence in primary membranous nephropathy.